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AbsTrACT
background and objective stent-assisted coil 
embolization is a well-established treatment of 
intracranial wide-necked aneurysms. The neuroform 
atlas stent system is a new generation microstent 
designed to enhance coil support, conformability, 
deliverability, and improve deployment accuracy. We 
present the 1-year efficacy and angiographic results of 
the humanitarian Device exemption (hDe) cohort from 
the atlas investigational Device exemption (iDe) clinical 
trial.
Method The atlas iDe trial is a prospective, multicenter, 
single-arm, open-label study of unruptured wide-necked 
intracranial aneurysms treated with the neuroform 
atlas stent and approved coils. The primary efficacy 
endpoint was the rate of 12-month complete aneurysm 
angiographic occlusion (raymond class i) without 
target aneurysm retreatment or significant parent artery 
stenosis (>50%) at the target location. The primary 
safety endpoint was the rate of major ipsilateral stroke 
or neurological death within 12 months. imaging core 
laboratory and clinical eventscommittee adjudicated the 
primary endpoints.
results 30 patients were enrolled at eight Us centers, 
with 27 patients completing the 12-month angiographic 
follow-up. The mean age was 59.4±11.8 years and 
24/30 patients (80%) were women. The mean aneurysm 
size was 5.3±1.7 mm and the dome:neck ratio was 
1.1±0.2. Procedural technical success of neuroform 
atlas stent deployment was 100%. 27 patients 
completed 12-month angiographic follow-up and 30 
patients completed their 6-month follow-up. When 
applying the last observation carried forward method, 
the primary efficacy endpoint was observed in 26/30 
patients (86.7%, 95% ci 69.3% to 96.2%) compared 
with 25/27 patients (92.6%, 95% ci 75.7% to 99.1%) 
who completed the 12-month angiographic follow-up. 
The primary safety endpoint of stroke occurred in one 
patient (3.3%), who made a complete clinical recovery at 
discharge. There were no neurological deaths.
Conclusion The neuroform atlas stent in conjunction 
with coils demonstrated a high rate of complete 
aneurysm occlusion at 12-month angiographic follow-up, 
with an improved safety profile in the hDe cohort.
Clinical  trial. gov registration 
number ncT0234058;results
INTroDuCTIoN
Stent-assisted coil embolization is a well-established 
endovascular approach for treating wide-necked 
intracranial aneurysms and has expanded the 
proportion of patients amenable to endovascular 
therapy.1–5 The Neuroform Microdelivery Stent 
System (Stryker Neurovascular, Fremont, Cali-
fornia, USA) was the first device approved by the 
Food and Drug Administration (FDA) via a Human-
itarian Device Exemption (HDE) in 2002 to treat 
wide-necked intracranial aneurysms, and subse-
quent product iterations (Neuroform EZ and EZ3) 
were approved via HDE supplements.
The Neuroform Atlas Stent System is a new 
generation Neuroform stent with design enhance-
ments to allow for a lower profile delivery (via 
0.0165 inch inner diameter microcatheter versus 
0.027 inch inner diameter microcatheter), better 
scaffolding due to smaller cell sizes, improved 
trackability, and higher conformability to the vessel 
wall than the previous generation Neuroform 
microstents (figure 1).
Here we present the 1-year results for the first 30 
patients enrolled in the prospective Atlas Investiga-
tional Device Exemption (IDE) study.
MeThoD
The Atlas IDE study was a prospective multi-
center, open-label, single-arm, stent-assisted wide-
necked intracranial saccular aneurysm coiling study 
approved by the Institutional Review Board at each 
participating site. The national principal investiga-
tors (OOZ and BTJ) have full access to the data and 
statistical analysis support.
enrollment, inclusion and exclusion criteria
Patients were considered enrolled in the study if they 
met all the inclusion criteria and none of the exclu-
sion criteria and signed the informed consent form. 
Key inclusion criteria were: 18–80 years of age, 
wide-necked intracranial aneurysm (neck ≥4 mm or 
dome-to-neck ratio <2), parent vessel diameter of 
2.0–4.5 mm, the aneurysm is intracranial (encom-
passing the entire posterior circulation and aneurysms 
at or distal to the superior hypophyseal artery in the 
anterior circulation). The key exclusion criteria were: 
multiple untreated intracranial aneurysms, acutely 
ruptured aneurysm within 14 days of enrollment, 
Hunt and Hess (H&H) scale ≥3 or modified Rankin 
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scale (mRS) of ≥4, intracranial mass or vascular malformation, 
prior treatment with stent-assisted coil embolization, Moyamoya 
disease, underlying parent artery atherosclerosis, and/or absolute 
contraindication to angiography or antiplatelet therapy (online 
supplementary table I).
Clinical and imaging follow-up schedule
All patients enrolled in the HDE cohort were followed up clini-
cally through hospital discharge and at 2±1 months, 6±1 months, 
and 12±2 months post-procedure for the following assessments: 
neurological evaluation, National Institute of Health Stroke Scale 
(NIHSS), mRS, H&H scale as appropriate, antiplatelet regimen 
compliance, adverse events, and Quality of Life assessment. Digital 
subtraction angiography was required at 12±2 months to deter-
mine the rate of complete aneurysm occlusion.
Primary efficacy outcome
The primary study efficacy outcome was the 12-month angio-
graphic complete aneurysm occlusion rate (defined as 100% 
angiographic occlusion or Raymond class I,6 7 see online 
Figure 1 Neuroform Atlas stent design attributes.
Figure 2 A middle-aged patient with 9 mm internal carotid artery-terminus aneurysm with contralateral access via SL-10 microcatheter, avoiding 
Y-stent, and demonstrating the trackability of the Neuroform Atlas stent (upper row), with complete occlusion at 12 months follow-up (lower row).
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supplementary figure 1) without retreatment and without parent 
artery stenosis (>50%) at the target location. The occlusion rate 
was assessed by an independent imaging core laboratory (UCSF 
Interventional Radiology Research Laboratory).
Primary safety outcome
The primary safety endpoint was the rate of any major ipsilat-
eral stroke or neurological death within 12 months following 
the procedure. Safety data were compared with a performance 
goal based on published rates of procedural and long-term 
morbidities for an aneurysm primary coiling, balloon-assisted 
coiling, or stent-assisted coiling. An independent Clinical Events 
Committee adjudicated prespecified primary endpoint events 
and serious device-related events.
secondary study outcomes
The study also evaluated the following secondary endpoints: 
(1) technical success (defined as the proportion of patients in 
whom the Neuroform Atlas stent was successfully delivered and 
deployed at the target aneurysm neck location), (2) incidence of 
post-procedural major ipsilateral stroke, (3) incidence of site-re-
ported device-related serious adverse events, (4) functional clin-
ical outcome as defined by the mRS, (5) all-cause mortality, (6) 
rate of target aneurysm occlusion and recanalization, (7) target 
aneurysm retreatment rate, (8) stent migration at the 12-month 
angiogram, and (9) parent artery patency at 12 months post 
procedure.
Device description
The Neuroform Atlas stent is a laser cut, nitinol, self-expanding 
microstent. It has a unique hybrid design with closed cells 
proximally to facilitate microcatheter re-crossing and open 
cells distally to allow for better anchoring and wall apposition 
(figure 1). These changes from the Neuroform EZ were intended 
to reduce foreshortening and enhance the stent deliverability, 
wall apposition, and coil scaffolding (see online supplementary 
table II comparing the Neuroform Atlas stent with the Neuro-
form EZ stent).
The stent is available in three diameter sizes (3.0, 4.0, and 
4.5 mm) and four length sizes (15, 21, 24, and 30 mm) and 
intended for use in vessel sizes of 2–4.5 mm in diameter 
(see online supplementary table III). For each given diameter, the 
stent will expand another 0.5 mm if unconstrained. The sheath 
and delivery wire are used to transfer the stent into a 0.0165–
0.0170 inch inner diameter Excelsior SL-10 or XT-17 micro-
catheter (Stryker Neurovascular, Fremont, California, USA), 
compared with the Neuroform EZ stent which requires a larger 
inner diameter (0.027 inch) microcatheter.
Procedure description
Patients who were considered for treatment were pretreated 
with daily oral aspirin (81–325 mg) and clopidogrel (75 mg) 
for at least 5 days before the procedure, including the day of 
the procedure. A loading dose of 325 mg aspirin and 300 mg 
clopidogrel the day before the procedure or 650 mg aspirin 
and 600 mg clopidogrel administered at least 6 hours prior to 
the procedure was allowed. Platelet function assays were not 
mandatory per the protocol. Intra-procedure anticoagulation 
and monitoring using intravenous heparin to maintain activated 
clotting time between 250–300 s were recommended as per the 
study site standard of care.
The aneurysm neck was crossed using the Excelsior SL-10 
or XT-17 microcatheter over a 0.14 inch microguidewire. The 
Neuroform Atlas stent was then transferred into the microcath-
eter via the loading sheath followed by advancement with the 
delivery wire to the distal end of the microcatheter. The stent 
was deployed across the neck of the aneurysm by stabilizing the 
delivery wire and withdrawing the microcatheter using a pin and 
pull technique.
The aneurysm was coiled by either re-crossing the stent with 
the microcatheter or jailing a second microcatheter within the 
aneurysm. Baseline and post-coiling images were required. All 
images were transferred to the core imaging laboratory after the 
procedure for independent adjudication. Medical records were 
provided to the Clinical Events Committee if an adverse event 
required adjudication. Following the procedure, patients were 
maintained on dual antiplatelet therapy for at least 3 months 
and aspirin for life. Figure 2 is an example of this procedural 
approach.
resulTs
Thirty patients were enrolled between June 30, 2015 and 
September 24, 2015. All 30 patients completed clinical and 
imaging follow-up at 6 months, and 27/30 patients completed 
in-person 12-month clinical follow-up within or outside the 
study 12-month time window. Three patients who missed the 
in-person 12-month clinical follow-up were contacted by tele-
phone, confirming no serious adverse event. A total of 27/30 
patients completed the angiographic follow-up by February 3, 
2017; 26 within the 12-month time window and one patient 
outside the 12-month time window. Data lock took place in 
March 2017. FDA approval under the HDE pathway was 
obtained on November 2, 2017.
All patients were successfully treated with the Atlas stent-as-
sisted coil embolization as intended. The mean patient age was 
59.4±11.8 years. Patients were predominantly female (80.0%) 
and white (83.3%) (table 1). Hypertension was the most 
common comorbidity (73.3%), followed by hyperlipidemia 
(56.7%). Current smokers comprised 30% of the patients. Five 
aneurysms had been previously treated; two by coiling and three 
by clipping. The target aneurysm was previously ruptured in two 
patients, although no patients were treated within 3 months of 
rupture. The mean aneurysm size (calculated as the maximum 
of height, width or depth) was 5.3±1.7 mm. Mean aneurysm 
neck width was 3.9±1.1 mm (range 1.6–7.0 mm) and 100% 
of patients had a dome:neck ratio <2. The majority (80.0%) 
of the treated aneurysms were in the anterior circulation. The 
anterior communicating artery was the most common aneurysm 
location (54.2%) in the anterior circulation, while the basilar 
apex (50.0%) was the most common location in the posterior 
circulation (table 1).
Procedural details and technical success
Procedural technical success was achieved in all patients. Mean 
procedure duration was 115.6±54.5 min (range 40–235 min). 
The majority of patients (90.0%) were implanted with a single 
stent. Three patients (10.0%) were implanted with two stents in a 
pre-planned manner to form a Y-stent configuration. The overall 
success rate of attempted stent implantation, on a per device 
basis, was 97.1% (33/34). One stent did not transfer from the 
storage sheath to the microcatheter hub and was not deployed, 
thus requiring a second device that deployed successfully.
Primary efficacy endpoints
When the three patients missing 12-month angiographic data 
were imputed using the last observation carried forward method, 
the overall complete occlusion rate (Raymond class I) was 86.7% 
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(26/30) (95% CI 69.3%, 96.2%). Of these patients, 83.3% 
(25/30) (95% CI 65.3% to 94.4%) met the composite primary 
efficacy endpoint of complete occlusion with no retreatment or 
significant parent artery stenosis at the target location (table 2).
The complete occlusion rate (Raymond class I) was 92.6% 
(25/27) (95% CI  75.7% to 99.1%) of patients who completed 
the 12-month angiographic follow-up (table 2). No patients 
required retreatment and one subject had >50% target location 
stenosis, yielding an occlusion rate without stenosis of 88.9% 
(95% CI  70.8% to 97.6%) in patients with available 12-month 
angiographic data.
Primary safety endpoints
No neurological death occurred within 12 months of follow-up. 
One patient (3.3% (95% CI 0.1% to 17.2%)) met the primary 
safety endpoint of major ipsilateral stroke (table 2). The subject 
developed confusion with slowing of speech and right-sided 
weakness a few hours after the procedure and demonstrated 
punctate foci of acute ischemic injury on MRI. The symptoms 
resolved within 48 hours. The patient was discharged home with 
a mRS score of 0. This was reported as a procedural stroke . 
The independent Clinical Event Committee (CEC) adjudicated 
the event as a major ipsilateral stroke that was both device- and 
procedure-related.
secondary study endpoints
One subject (1/27; 3.7%) had severe stenosis (defined as 71–99%) 
of the parent target artery at 12 months. This subject experi-
enced no clinical serious adverse events and all mRS and NIHSS 
scores were 0 throughout the 12-month follow-up period. There 
was no evidence of stent migration or thromboembolism in 
Table 1 Baseline demographics and aneurysm characteristics
n=30 Patients/30 
Aneurysms
Age (years)
  Mean±SD (N) 59.4±11.8 (30)
  Median (Q1–Q3) 58.5 (53.0–68.0)
  Min–Max 31.0–79.0
Height (cm)
  Mean±SD (N) 164.5±9.7 (30)
  Median (Q1–Q3) 161.1 (157.5–167.6)
  Min–Max 152.4–195.6
Weight (kg)
  Mean±SD (N) 77.6±19.6 (30) 
  Median (Q1–Q3) 73.5 (65.4–90.9) 
  Min–Max 45.6–142.0 
Body mass index
  Mean±SD (N) 28.5±5.4 (30)
  Median (Q1–Q3) 26.7 (25.3–31.7)
  Min–Max 19.6–38.4
Gender, female 80.0% (24/30)
Race, white 83.3% (25/30)
Comorbidities
  Coronary artery disease 16.7% (5/30)
  Chronic obstructive pulmonary disorder  23.3% (7/30)
  Hyperlipidemia/hypercholesterolemia  56.7% (17/30)
  Hypertension 73.3% (22/30)
  Diabetes mellitus 30.0% (9/30)
  Current smoker 30.0% (9/30)
  Past smoker 43.3% (13/30)
  Previous transient ischemic attack 13.3% (4/30)
  Previous ischemic stroke 13.3% (4/30)
  Previous hemorrhagic stroke 10.0% (3/30)
  Previously ruptured target aneurysm 6.7% (2/30)
  History of multiple aneurysms 16.7% (5/30)
  Other significant medical history* 80.0% (24/30)
Anterior circulation aneurysm location 80.0% (24/30)
Aneurysm size (mm)†
  Mean±SD (N) 5.3±1.7 (30)
  Median (Q1–Q3) 5.3 (4.0–6.7)
  Min–Max 2.5–9.0
Aneurysm neck width (mm)
  Mean±SD (N) 3.9±1.1 (30)
  Median (Q1–Q3) 4.0 (3.2–4.4)
  Min–Max 1.6–7.0
Dome:neck ratio‡
  Mean±SD (N) 1.1±0.2 (28)
  Median (Q1–Q3) 1.1 (1.1–1.3)
  Min–Max 0.6–1.5
Parent vessel diameter proximal and distal to the aneurysm neck (mm)
  Mean±SD (N) 2.9±0.6 (30), 2.6±0.6 (30) 
Continued
n=30 Patients/30 
Aneurysms
  Median (Q1–Q3) 2.9 (2.3–3.3), 2.4 
(2.1–3.0)) 
  Min–Max 2.0–4.4, 2.0–4.5 
Exact aneurysm location
  Anterior communicating artery 43.3% (13/30)
  Middle cerebral artery bifurcation 10% (3/30)
  ICA–ophthalmic artery 6.7% (2/30)
  ICA–posterior communicating artery 3.3% (1/30)
  ICA bifurcation/terminus 3.3% (1/30)
  Supraclinoid carotid artery 10% (3/30)
  Superior hypophyseal 3.3% (1/30)
  Basilar apex 10% (3/30)
  Basilar trunk 3.3% (1/30)
  Superior cerebellar artery 3.3% (1/30)
  Vertebrobasilar junction 3.3% (1/30)
*Other significant medical history included 114 reports of other findings in 24 
patients. The most frequently reported findings were headaches/migraines (n=14), 
dizziness (n=7), neck/back pain (n=5), seizures (n=4), and gastroesophageal reflux 
disease (n=4). All other significant medical history findings were reported to occur 
in three or fewer patients.
†Aneurysm size calculated as a maximum of three dimensions (anteroposterior 
plane, lateral plane, height).
‡Dome size calculated as a minimum of two widths (anteroposterior plane, lateral 
plane).
ICA, internal carotid artery.
Table 1 Continued 
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any of the 27 cases evaluated at 12 months. Apposition of the 
Neuroform Atlas stent to the parent artery wall was noted to 
be excellent in all cases by the core laboratory. Core laboratory 
analysis confirmed that perforators or branch arteries covered 
by the stent remained patent at the 12-month follow-up in all 
evaluable patients (25/27; 92.6% (95% CI 75.7% to 99.1%)). In 
one subject the branch artery/perforator was not clearly patent 
at 12 months, but no clinical adverse events were reported. In 
another subject the images were not evaluable (1/27; 3.7%). No 
patients in this cohort experienced a site-reported device-related 
serious adverse event. One subject experienced intra-procedural 
subarachnoid hemorrhage due to aneurysm rupture caused by 
coil packing, with no neurological deficit other than a head-
ache. The patient was classified as H&H scale 2 post-procedure 
with mRS 1 (due to a headache) and was scored the same at all 
follow-up visits.
At the 12-month follow-up, NIHSS scores were obtained for 
25 of the 27 patients who had clinic visits, with a mean NIHSS 
score of 0.2±0.4. NIHSS scores were not available for five 
patients due to missed visits (3/5) or missed NIHSS assessments 
(2/5). At the 12-month follow-up, mRS scores were available 
for 25 patients, all of whom had mRS scores of 0 or 1 (25/25; 
100.0%). Twenty-three (23/25; 92.0%) patients had mRS scores 
of 0 and two patients (2/25; 8.0%) had mRS scores of 1 (one of 
which was due to a headache). The mRS scores were not avail-
able for two of the 27 patients who completed the 12-month 
visit. Of the three patients who did not complete the 12-month 
visit, two were contacted by the site and the telephone inter-
view mRS assessment score was 0.
DIsCussIoN
The Neuroform Atlas Stent System demonstrated excellent effi-
cacy and safety in treating wide-necked intracranial aneurysms. 
The HDE cohort showed a high rate of complete aneurysm 
occlusion of 86.7%, without restenosis or retreatment in 83.3% 
of patients, and a low risk of ipsilateral stroke with 100% of 
patients achieving normal or near normal neurological function 
(mRS 0–1) at 1-year follow-up without any neurological death.
The HDE cohort study results are comparable with previously 
published stent-assisted coiling data.8-12 In a 2016 meta-anal-
ysis of 14 observational studies involving 2698 mixed open and 
closed cell type stent-assisted coiling,1 the pooled immediate 
occlusion rate for stent-assisted coiling was 57.7% (range 20.2–
89.2%) versus 60% (95% CI 40.6% to 77.3%) for the Atlas 
HDE cohort. The long-term occlusion rate was 87.6% in the 
meta-analysis compared with 92.6% in our study. The mortality 
rate was 1.4% (range 0–27.5%) compared with 0% in the 
current Atlas HDE cohort.
In an earlier 2014 meta-analysis of 47 studies comparing the 
first-generation open cell Neuroform and closed cell Enter-
prise stents (Cerenovus, New Brunswick, New Jersey, USA), 4238 
aneurysms were treated with stent-assisted coil embolization with a 
mean follow-up of 14.1 months.2 The overall initial and long-term 
100% complete occlusion rates were 53% and 69%, respectively, 
versus 60% and 92.6% in the Atlas HDE cohort, respectively. 
Similarly, the safety profile compares well in the Atlas HDE cohort 
compared with this meta-analysis (permanent morbidity and 
mortality were 3.9%, and 2.3%, respectively, versus 3.3% and 0% 
(95% CI 0% to 11.6%), respectively, in the Atlas HDE cohort).
The results of the Atlas HDE cohort compare favorably with 
those of the braided design aneurysmal microstent study. For 
example, a recent LVIS stent (MicroVention, Aliso Viejo, Cali-
fornia, USA) HDE study of 31 patients reported a technical 
success rate of 93.1% with ≥90% occlusion rate of 92.9% and 
complete occlusion rate of 75% at 6 months angiography, with 
0% morbidity and mortality.8 Another 30 patient multicenter 
retrospective study using the braided LVIS Jr microstent demon-
strated 3.3% morbidity rate with no mortality and complete 
Table 2 Core Laboratory angiographic and Clinical Event Committee safety primary endpoints
Core laboratory angiographic occlusion 
findings
Post-procedure 12 Months 12 Months
n=30 (95% CI) n=27 (95% CI) n=30 (95% CI)
by available angiography Imputed by loCF*
Raymond class
  Complete 100% occlusion (Class I) 60.0% (18/30) (40.6% to 77.3%) 92.6% (25/27) (75.7% to 99.1%) 86.7% (26/30) (69.3% to 96.2%)
  With no stenosis (≤50%) 60.0% (18/30) (40.6% to 77.3%) 88.9% (24/27) (70.8% to 97.6%) 83.3% (25/30) (65.3% to 94.4%)
  Residual neck† (Class II) 26.7% (8/30) (12.3% to 45.9%) 0.0% (0/27) (0.0% to 12.8%) 0.0% (0/30) (0.0% to 11.6%)
  Residual aneurysm‡ (Class III) 10.0% (3/30) (2.1% to 26.5%) 7.4% (2/27) (0.9% to 24.3%) 10.0% (3/30) (2.1% to 26.5%)
  Not assessable 3.3% (1/30) (0.1% to 17.2%) 0.0% (0/27) (0.0% to 12.8%) 3.3% (1/30) (0.1% to 17.2%)
Parent artery stenosis
  0–25% 100.0% (30/30) (88.4% to 100.0%) 96.3% (26/27) (81.0% to 99.9%) 93.3% (28/30) (77.9% to 99.2%)
  26–50% 0.0% (0/30) (0.0% to 11.6%) 0.0% (0/27) (0.0% to 12.8%) 3.3% (1/30) (0.1% to 17.2%)
  51–70% 0.0% (0/30) (0.0% to 11.6%) 0.0% (0/27) (0.0% to 12.8%) 0.0% (0/30) (0.0% to 11.6%)
  71–99% 0.0% (0/30) (0.0% to 11.6%) 3.7% (1/27) (0.1% to 19.0%) 3.3% (1/30) (0.1% to 17.2%)
Clinical event Committee adjudicated safety 
endpoint % Patients (n/N) 95% CI§
Any major ipsilateral stroke or neurological death 3.3% (1/30) 0.1% to 17.2%
Major ipsilateral stroke 3.3% (1/30) 0.1% to 17.2%
Neurological death/permanent disability 0.0% (0/30) 0.0% to 11.6%
*LOCF, last observed carried forward.
†95–99% aneurysm occlusion.
‡<95% aneurysm occlusion.
§Clopper–Pearson exact CI.
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New Devices
occlusion rate of 76% (21/25) Raymond class I on a mean 
follow-up of 5.2 months, with one patient reporting perma-
nent complications (3.3%).9 The Canadian LVIS Jr multicenter 
registry of 102 patients demonstrated a complete long-term 
occlusion rate (defined as Raymond class I) of 68%, with 3% 
permanent neurological deficits, and 1% overall mortality rate.10
A recently published result of a retrospective Neuroform 
Atlas stent-assisted coil embolization single-center experience 
which examined 48 patients with 55 aneurysms was consistent 
with our HDE cohort findings.11 In their study the microstent 
was deployed via different 0.0165–0.017 inch microcatheters 
and the Eclipse-2 balloon (Balt, France), which resulted in 100% 
technical success rate with an 83.7% complete occlusion rate at 
mean follow-up of 8.7 months. The safety profile demonstrated 
one minor stroke in one patient (1/48; 2%) and no neurological 
death (0%).11
In summary, the newly designed Neuroform Atlas stent 
provides potential advantages over Neuroform EZ and LVIS 
stents (see online supplementary tables II and III). First, its 
compatibility with a 0.165 inch inner diameter microcatheter 
across all Atlas stent diameter and length sizes makes it practical 
in all aneurysm locations. Second, its higher number of connecter 
and alternating cell numbers from 8 to 12 provides better scaf-
folding and coil stability within the aneurysm lumen. Third, the 
accuracy of deployment is very high with less foreshortening 
than braided stents. Fourth, the conformability around acute 
angles is an advantage of the open cell design with alternating 
cell size design. However, the lack of re-sheathability remains a 
challenge to the open design nitinol stents.
study limitations
Despite the independent core laboratory, Clinical Event 
Committee, and prospective study design, this is still a small 
sample size study. In addition, most of the aneurysms in the 
current cohort are small in size, with an interquartile median size 
ranging between 4 and 6.7 mm. The smaller aneurysms are less 
likely to recur and potentially have a higher chance of progres-
sive occlusion over time. A further limitation is the lack of data 
on how the decision to treat these small aneurysms is made. One 
assumption is that it might be related to the evolution of the field 
and clinical practice pattern of treating smaller aneurysms due 
to enhanced safety and efficacy profiles of endovascular therapy 
over time. However, this is also likely to be related to a multifac-
torial complex decision-making process to proceed with aneu-
rysm treatment. This might be related, in part, to aneurysm size, 
shape, location, risk factors known to increase future risk of 
aneurysm rupture, and patient anxiety.
CoNClusIoN
Neuroform Atlas stent-assisted coil embolization was associated 
with high 1-year complete occlusion rates and favorable safety 
profiles in patients with wide-necked aneurysms. Particularly 
encouraging was the increase in Raymond I occlusion rates from 
60% immediately post-procedure to 86.7% at 1 year.12 Another 
important observation from the current study is the fact that the 
majority of the aneurysm (three-quarters) are less than 7 mm in 
size, reflective of the changing practice of treating smaller size 
aneurysms with stent-assisted coiling.
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